U.S. market Closed. Opens in 2 hours 54 minutes

CUE | Cue Biopharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.0502 - 1.1697
52 Week Range 0.4500 - 3.25
Beta 2.17
Implied Volatility 353.35%
IV Rank 47.12%
Day's Volume 408,699
Average Volume 733,973
Shares Outstanding 63,350,300
Market Cap 69,051,827
Sector Healthcare
Industry Biotechnology
IPO Date 2018-01-02
Valuation
Profitability
Growth
Health
P/E Ratio -1.20
Forward P/E Ratio N/A
EPS -0.91
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 53
Country USA
Website CUE
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
*Chart delayed
Analyzing fundamentals for CUE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is weak. For more detailed analysis please see CUE Fundamentals page.

Watching at CUE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CUE Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙